BriaCell Therapeutics Corp. (BCTX)
Oxford Ledge is still expanding full research coverage of BCTX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
BriaCell develops whole-cell cancer immunotherapies with patent protection across multiple countries and regulatory oversight from the FDA.
SEC filings
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-06-26
- 10-Q Quarterly financial report (unaudited) 2026-06-09
- 8-K Entry into material agreement; 3.02; Other material event; Financial statements and exhibits 2026-06-03
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-03-31
- 10-Q Quarterly financial report (unaudited) 2026-03-10
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for BCTX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open BCTX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.